Compare Stocks: SPRY, HRMY, OCUL, and HCM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$12.56 +3.0%	$11.16	$9.77 ▼ $18.30	$2.13B	0.23	43,463 shs	89,210 shs
HRMY Harmony Biosciences	$38.14 +0.1%	$36.01	$25.52 ▼ $40.87	$2.22B	0.96	863,266 shs	734,283 shs
OCUL Ocular Therapeutix	$10.65 +6.1%	$9.34	$6.23 ▼ $16.44	$2.20B	0.93	2.11 million shs	11.15 million shs
SPRY ARS Pharmaceuticals	$6.24 +10.4%	$7.52	$4.91 ▼ $15.09	$561.06M	0.98	2.57 million shs	2.50 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	+2.95%	+0.08%	+15.87%	+4.15%	-23.65%
HRMY Harmony Biosciences	+0.05%	-2.21%	+12.94%	+25.30%	+3.44%
OCUL Ocular Therapeutix	+6.08%	+15.26%	+18.73%	+33.29%	-15.61%
SPRY ARS Pharmaceuticals	+10.44%	+5.58%	-10.86%	-12.97%	-57.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$12.56 +3.0%	$11.16	$9.77 ▼ $18.30	$2.13B	0.23	43,463 shs	89,210 shs
HRMY Harmony Biosciences	$38.14 +0.1%	$36.01	$25.52 ▼ $40.87	$2.22B	0.96	863,266 shs	734,283 shs
OCUL Ocular Therapeutix	$10.65 +6.1%	$9.34	$6.23 ▼ $16.44	$2.20B	0.93	2.11 million shs	11.15 million shs
SPRY ARS Pharmaceuticals	$6.24 +10.4%	$7.52	$4.91 ▼ $15.09	$561.06M	0.98	2.57 million shs	2.50 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	+2.95%	+0.08%	+15.87%	+4.15%	-23.65%
HRMY Harmony Biosciences	+0.05%	-2.21%	+12.94%	+25.30%	+3.44%
OCUL Ocular Therapeutix	+6.08%	+15.26%	+18.73%	+33.29%	-15.61%
SPRY ARS Pharmaceuticals	+10.44%	+5.58%	-10.86%	-12.97%	-57.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.17	Hold	$14.87	18.37% Upside
HRMY Harmony Biosciences	2.30	Hold	$45.50	19.30% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	141.78% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$28.20	351.92% Upside

Current Analyst Ratings Breakdown

Latest SPRY, HRMY, OCUL, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	OCUL Ocular Therapeutix	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	HRMY Harmony Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2026	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$39.00
8/5/2026	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$29.00 ➝ $34.00
8/5/2026	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$37.00
8/4/2026	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$70.00
8/4/2026	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/4/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/31/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
7/31/2026	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$50.00 ➝ $51.00
7/23/2026	HCM HUTCHMED	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$16.00 ➝ $14.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$548.51M	4.00	$2.77 per share	4.53	$7.17 per share	1.75
HRMY Harmony Biosciences	$868.45M	2.56	$3.18 per share	11.99	$15.11 per share	2.52
OCUL Ocular Therapeutix	$51.95M	45.02	N/A	N/A	$3.07 per share	3.47
SPRY ARS Pharmaceuticals	$84.28M	7.35	N/A	N/A	$1.16 per share	5.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$456.91M	N/A	N/A	57.09	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	$158.69M	$3.08	12.38	9.58	0.35	18.88%	20.06%	14.15%	11/3/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	N/A

Latest SPRY, HRMY, OCUL, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/4/2026	Q2 2026	HRMY Harmony Biosciences	$0.9560	$1.28	+$0.3240	$1.28	$250.77 million	$261.28 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.06	5.64	5.50
HRMY Harmony Biosciences	0.13	3.48	3.45
OCUL Ocular Therapeutix	0.14	13.10	13.03
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
HRMY Harmony Biosciences	86.23%
OCUL Ocular Therapeutix	59.21%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
HRMY Harmony Biosciences	11.00%
OCUL Ocular Therapeutix	3.10%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable
HRMY Harmony Biosciences	200	58.24 million	51.83 million	Optionable
OCUL Ocular Therapeutix	230	219.62 million	212.81 million	Optionable
SPRY ARS Pharmaceuticals	90	99.30 million	65.74 million	Optionable

SPRY, HRMY, OCUL, and HCM Headlines

Recent News About These Companies

Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit

August 17 at 7:11 PM | prnewswire.com

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm

August 17 at 6:00 PM | globenewswire.com

SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi ...

August 17 at 2:08 PM | caledonianrecord.comC

ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.6% Higher - Here's Why

August 17 at 1:19 PM | marketbeat.com

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

August 17 at 12:42 PM | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

August 17 at 12:00 PM | globenewswire.com

Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026

August 17 at 11:45 AM | newsfilecorp.comN

SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky

August 17 at 11:24 AM | globenewswire.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Rating of "Moderate Buy" by Brokerages

August 17 at 3:16 AM | americanbankingnews.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

August 16 at 8:01 PM | prnewswire.com

SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

August 16 at 2:10 PM | newsfilecorp.comN

ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

August 16 at 8:31 AM | globenewswire.com

Cantor Fitzgerald Remains a Buy on ARS Pharmaceuticals (SPRY)

August 15 at 11:53 PM | theglobeandmail.com

ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

August 15 at 11:53 AM | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

August 15 at 10:00 AM | globenewswire.com

Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026

August 14, 2026 | newsfilecorp.comN

Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026

August 14, 2026 | theglobeandmail.com

ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises

August 14, 2026 | finance.yahoo.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

August 14, 2026 | newsfilecorp.comN

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings

August 14, 2026 | marketbeat.com

The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY

August 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, HRMY, OCUL, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

$12.56 +0.36 (+2.95%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$12.62 +0.05 (+0.44%)

As of 05:20 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Harmony Biosciences NASDAQ:HRMY

$38.14 +0.02 (+0.05%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$37.93 -0.21 (-0.55%)

As of 04:39 AM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Ocular Therapeutix NASDAQ:OCUL

$10.65 +0.61 (+6.08%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$10.59 -0.06 (-0.56%)

As of 06:04 AM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$6.24 +0.59 (+10.44%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$6.21 -0.03 (-0.48%)

As of 05:44 AM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRY, HRMY, OCUL, and HCM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRY, HRMY, OCUL, and HCM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRY, HRMY, OCUL, and HCM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, HRMY, OCUL, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

Harmony Biosciences NASDAQ:HRMY

Ocular Therapeutix NASDAQ:OCUL

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRY, HRMY, OCUL, and HCM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRY, HRMY, OCUL, and HCM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRY, HRMY, OCUL, and HCM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY, HRMY, OCUL, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

Harmony Biosciences NASDAQ:HRMY

Ocular Therapeutix NASDAQ:OCUL

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools